Xencor (NASDAQ:XNCR) focuses on developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma, and allergic diseases. The company's technology platform is designed to improve the function and clinical utility of antibody therapeutics. Xencor’s pipeline includes novel antibody candidates currently in clinical development, aimed at providing new treatment options for patients in need. With a commitment to innovation, Xencor's objective is to leverage its XmAb® technology platform to create and develop advanced therapeutic antibodies that can potentially transform the way diseases are treated.